Huang Jie, Wang Xiang, Zhang Xue, Chen Weijie, Luan Lijuan, Song Qi, Wang Hao, Liu Jia, Xu Lei, Xu Yifan, Shen Licheng, Tan Lijie, Jiang Dongxian, Su Jieakesu, Hou Yingyong
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Front Genet. 2021 Apr 29;12:616110. doi: 10.3389/fgene.2021.616110. eCollection 2021.
In the present study, we aimed to investigate the clinical and prognostic values of amplification and improve the risk stratification in patients with esophageal squamous cell carcinoma. amplification was analyzed by fluorescence hybridization using tissue microarray consisting of representative tissues of 520 patients with esophageal squamous cell carcinoma, and its correlation with clinicopathological features and clinical outcomes were evaluated. amplification was found in 8.5% (44/520) of patients with esophageal squamous cell carcinoma. amplification was negatively correlated with disease progression ( = 0.003) and death ( = 0.006). Patients with amplification showed a significantly better disease-free survival ( = 0.016) and overall survival ( = 0.023) compared with those patients without amplification. When patients were further stratified into I-II stage groups and III-IV stage groups, amplification was significantly associated with both better disease-free survival ( = 0.023) and overall survival ( = 0.025) in the I-II stage group rather than the III-IV stage group. On univariate and multivariate analysis, invasive depth and amplification were associated with disease-free survival and overall survival. Taken together, amplification was identified as an independent prognostic factor for survival, which could be incorporated into the tumor-node-metastasis staging system to refine risk stratification of patients with esophageal squamous cell carcinoma.
在本研究中，我们旨在探讨[具体指标]扩增的临床和预后价值，并改善食管鳞状细胞癌患者的风险分层。采用包含520例食管鳞状细胞癌患者代表性组织的组织微阵列，通过荧光杂交分析[具体指标]扩增情况，并评估其与临床病理特征及临床结局的相关性。在8.5%（44/520）的食管鳞状细胞癌患者中发现了[具体指标]扩增。[具体指标]扩增与疾病进展（P = 0.003）和死亡（P = 0.006）呈负相关。与无[具体指标]扩增的患者相比，有[具体指标]扩增的患者无病生存期（P = 0.016）和总生存期（P = 0.023）显著更好。当患者进一步分为I-II期组和III-IV期组时，[具体指标]扩增在I-II期组而非III-IV期组中与更好的无病生存期（P = 0.023）和总生存期（P = 0.025）显著相关。单因素和多因素分析显示，浸润深度和[具体指标]扩增与无病生存期和总生存期相关。综上所述，[具体指标]扩增被确定为生存的独立预后因素，可纳入肿瘤-淋巴结-转移分期系统以优化食管鳞状细胞癌患者的风险分层。
